Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00590603 · ClinicalTrials.gov registry record · Phase 1
Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00590603 is a Phase 1 study that was terminated before completion, run by Duke University. The registered enrollment target is 25 participants.
The verdict
NCT00590603, a Phase 1 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a phase I dose escalation study to estimate the maximum tolerated dose (MTD) of the novel combination of Arsenic, Ascorbic Acid and Velcade, followed by a phase II study conducted using the MTD estimated from the phase I portion.
Interventions
- DRUG Arsenic Trioxide, Ascorbic Acid and Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-07 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00590603
The ClinicalTrials.gov registry entry for NCT00590603 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Arsenic Trioxide, Ascorbic Acid and Bortezomib is the first listed.
NCT00590603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00590603 about?
NCT00590603 is a clinical study titled "Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma". This is a phase I dose escalation study to estimate the maximum tolerated dose (MTD) of the novel combination of Arsenic, Ascorbic Acid and Velcade, followed by a phase II study conducted using the MTD estimated from the phase I portion.
What is the current status of trial NCT00590603?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2008-07. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00590603?
The interventions under investigation include: Arsenic Trioxide, Ascorbic Acid and Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00590603?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.